These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27008871)

  • 1. Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.
    Lamoth F; Damonti L; Alexander BD
    J Clin Microbiol; 2016 Jun; 54(6):1638-1640. PubMed ID: 27008871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry.
    Durán Graeff L; Seidel D; Vehreschild MJ; Hamprecht A; Kindo A; Racil Z; Demeter J; De Hoog S; Aurbach U; Ziegler M; Wisplinghoff H; Cornely OA;
    Mycoses; 2017 Apr; 60(4):273-279. PubMed ID: 28150341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination antifungals as an effective means of salvage in paediatric leukaemia patients with invasive fungal infections.
    Meena JP; Gupta AK; Jana M; Seth R
    Indian J Med Microbiol; 2019; 37(1):109-112. PubMed ID: 31424020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and clinical characteristics of invasive mould infections: A multicenter, retrospective analysis in five Asian countries.
    Rotjanapan P; Chen YC; Chakrabarti A; Li RY; Rudramurthy SM; Yu J; Kung HC; Watcharananan S; Tan AL; Saffari SE; Tan BH
    Med Mycol; 2018 Feb; 56(2):186-196. PubMed ID: 28525619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Challenges of Non-
    Lamoth F; Kontoyiannis DP
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis.
    Lamoth F; Chung SJ; Damonti L; Alexander BD
    Clin Infect Dis; 2017 Jun; 64(11):1619-1621. PubMed ID: 28199491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients.
    Peghin M; Monforte V; Martin-Gomez MT; Ruiz-Camps I; Berastegui C; Saez B; Riera J; Solé J; Gavaldá J; Roman A
    Transpl Infect Dis; 2016 Feb; 18(1):70-8. PubMed ID: 26678668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?
    Bassetti M; Vena A; Bouza E; Peghin M; Muñoz P; Righi E; Pea F; Lackner M; Lass-Flörl C
    Clin Microbiol Infect; 2020 Aug; 26(8):1024-1033. PubMed ID: 32120042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial.
    McGhee W; Michaels MG; Martin JM; Mazariegos GV; Green M
    J Pediatric Infect Dis Soc; 2016 Mar; 5(1):80-4. PubMed ID: 26908494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Issues in Antifungal Resistance.
    Perfect JR; Ghannoum M
    Infect Dis Clin North Am; 2020 Dec; 34(4):921-943. PubMed ID: 33131575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.
    Adler-Moore J; Lewis RE; Brüggemann RJM; Rijnders BJA; Groll AH; Walsh TJ
    Clin Infect Dis; 2019 May; 68(Suppl 4):S244-S259. PubMed ID: 31222254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections.
    Walsh TJ; Lewis RE; Adler-Moore J
    Clin Infect Dis; 2019 May; 68(Suppl 4):S241-S243. PubMed ID: 31222252
    [No Abstract]   [Full Text] [Related]  

  • 14. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy.
    Jenks JD; Reed SL; Seidel D; Koehler P; Cornely OA; Mehta SR; Hoenigl M
    Int J Antimicrob Agents; 2018 Nov; 52(5):706-712. PubMed ID: 30099056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal PK/PD considerations in fungal pulmonary infections.
    Lepak AJ; Andes DR
    Semin Respir Crit Care Med; 2011 Dec; 32(6):783-94. PubMed ID: 22167406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of in vitro antifungal susceptibility testing.
    Espinel-Ingroff A
    Rev Esp Quimioter; 2000 Jun; 13(2):161-6. PubMed ID: 10918088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China.
    Xie L; Zhai H; Zhao J; Sun S; Shi W; Dong X
    Am J Ophthalmol; 2008 Aug; 146(2):260-265. PubMed ID: 18547535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activity of butenafine against ocular pathogenic filamentous fungi in vitro].
    Xu Y; Pang GR; Zhao DQ; Gao CW; Zhou LT; Sun ST; Wang BL; Chen ZJ
    Zhonghua Yan Ke Za Zhi; 2010 Jan; 46(1):38-42. PubMed ID: 20388321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
    Hadrich I; Makni F; Neji S; Cheikhrouhou F; Bellaaj H; Elloumi M; Ayadi A; Ranque S
    Med Mycol; 2012 Nov; 50(8):829-34. PubMed ID: 22587728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virulence Attributes and Antifungal Susceptibility Profile of Opportunistic Fungi Isolated from Ophthalmic Infections.
    Sav H; Ozdemir HG; Altınbas R; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Oct; 181(9-10):653-61. PubMed ID: 27193295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.